Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)

导出原文传递

翻译打印收藏纠错

作者： Tinker,A.V. ^[1] ; Ellard,S. ^[2] ; Welch,S. ^[3] ; Moens,F. ^[4] ; Allo,G. ^[5] ; Tsao,M.S. ^[6] ; Squire,J. ; Tu,D. ; Eisenhauer,E.A. ; MacKay,H.

作者单位： NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada ^[1] Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, BC V5Z 4E6 ^[2] BC Cancer Agency, Centre for the Southern Interior, Kelowna, BC, Canada ^[3] Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, ON, Canada ^[4] London Regional Cancer Program, London, ON, Canada ^[5] Princess Margaret Hospital, University Health Network, Toronto, ON, Canada ^[6]

关键词 Cervical cancer systemic therapy Temsirolimus Phase II trial mTOR pathway

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交